Dublin biopharma developing GH001, a treatment for depression and other psychiatric conditions.
Founders
Theis Terwey(Germany · ♂)— He co-founded GH Research in 2018 to develop a proprietary inhalable 5-MeO-DMT formulation (GH001) for treatment-resistant depression, serving as founding CEO until 2024.
Magnus C. Halle(♂)— Co-founded GH Research to advance rapid-acting psychedelic therapeutics for mental-health disorders.
Team & hubs
Funding history
Date
Round
Amount
Apr 2021
Series B
Dublin biopharma GH Research raised a $125m Series B led by RA Capital and RTW Investments to advance trials of its depression drug GH001.
$125M
Investors
Tap an investor to see what else they have backed.